LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Anaplasma phagocytophilum

    Cosiquien, Ronin Joshua S / Stojiljkovic, Nenad / Nordstrom, Charles W / Amadi, Emeka / Lutwick, Larry / Dumic, Igor

    Infectious disease reports

    2023  Volume 15, Issue 4, Page(s) 354–359

    Abstract: Anaplasma ... ...

    Abstract Anaplasma phagocytophilum
    Language English
    Publishing date 2023-06-29
    Publishing country Switzerland
    Document type Case Reports
    ISSN 2036-7430
    ISSN 2036-7430
    DOI 10.3390/idr15040035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis.

    Dumic, Igor / Charokopos, Antonios / Parmar, Angadabir / Grant, Christopher R / Cosiquien, Ronin Joshua S / Dagnon da Silva, Marilia / Petcu, Emilia

    Medicina (Kaunas, Lithuania)

    2023  Volume 59, Issue 5

    Abstract: Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib. The ... ...

    Abstract Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib. The exact mechanism is unknown, and the literature lacks case reports of this phenomenon. Here, we report the case of a patient who developed thrombocytopenia 12 weeks after starting treatment with Nintedanib. The patient underwent an extensive work up for infectious, hematological, autoimmune, and neoplastic diseases. The patient's thrombocytopenia resolved following cessation of Nintedanib. This case is significant as it reports a rare side effect that might have detrimental consequences if not recognized and treated timely. Additionally, the onset of thrombocytopenia was delayed, 3 months after the initiation of Nintedanib. We also highlight the various literature regarding drug-induced thrombocytopenia and explore the necessary work-up needed to exclude other potential diagnoses. We hope to advocate for multidisciplinary teams to be aware of patients with pulmonary fibrosis on Nintedanib so that this adverse effect can be recognized promptly.
    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Indoles/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Thrombocytopenia/chemically induced ; Thrombocytopenia/drug therapy
    Chemical Substances nintedanib (G6HRD2P839) ; Indoles ; Protein Kinase Inhibitors
    Language English
    Publishing date 2023-05-22
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2188113-3
    ISSN 1648-9144 ; 1010-660X
    ISSN (online) 1648-9144
    ISSN 1010-660X
    DOI 10.3390/medicina59050999
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6270: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top